SCHEMBL17815746

SCHEMBL17815746

Cc1ccc(OCC2CC2(F)F)c(C)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.43
HTT P42858 1/20 0.43
HPGD P15428 4/20 0.42
LMNA P02545 1/20 0.42
KMT2A Q03164 3/20 0.40
MEN1 O00255 2/20 0.40
L3MBTL1 Q9Y468 4/20 0.39
RAB9A P51151 3/20 0.39
NPC1 O15118 2/20 0.39
NFKB1 P19838 1/20 0.39
NFKB2 Q00653 1/20 0.39
RELA Q04206 1/20 0.39
S1PR4 O95977 1/20 0.39
MAPT P10636 2/20 0.38
KDM4E B2RXH2 3/20 0.38
ALDH1A1 P00352 2/20 0.38
TSHR P16473 1/20 0.38
MAPK1 P28482 1/20 0.38
HSP90AA1 P07900 1/20 0.37
UBE2N P61088 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17815778 0.83 HTT (0.42) SMN1; SMN2HTTHPGDLMNAKMT2A
SCHEMBL879009 0.83 HTR1A (0.37) L3MBTL1MAPTALDH1A1
SCHEMBL17815728 0.82 SYK (0.47) HPGDS1PR4
SCHEMBL17811813 0.82 ACACB (0.39) SMN1; SMN2HTTLMNAL3MBTL1ALDH1A1
SCHEMBL15086894 0.76 ACACB (0.46) HPGDKMT2AMEN1L3MBTL1MAPT
SCHEMBL7953345 0.75 ALDH1A1 (0.64) SMN1; SMN2HPGDLMNAKMT2AMEN1
SCHEMBL7953349 0.75 ALDH1A1 (0.64) SMN1; SMN2HPGDLMNAKMT2AMEN1
SCHEMBL262508 0.75 ALDH1A1 (0.64) SMN1; SMN2HPGDLMNAKMT2AMEN1
SCHEMBL15969491 0.74 MBOAT4 (0.35)
SCHEMBL16172630 0.73 HPGD (0.54) SMN1; SMN2HPGDLMNAKMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160159815-A1 Fused Piperidine Amides as Modulators of Ion Channels VERTEX PHARMACEUTICALS INCORPORATED 2016-06-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160159815-A1 Fused Piperidine Amides as Modulators of Ion Channels TRPV1, TRPA1, KCNJ2 SMN1; SMN2 714/4885HTT 535/4885HPGD 1632/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.